Jaguar Animal Health Inc. (JAGX)
NASDAQ:JAGX
Want to see JAGX full AI Analyst Report?
Top Page
Jaguar Animal Health
(NASDAQ:JAGX)
Select Model
Select Model
Rating:43Neutral
Price Target:
$3.50
▲(173.44% Upside)
Action:Reiterated
Date:05/21/26
The score is primarily constrained by weak financial performance (large ongoing losses, negative equity, and renewed cash burn) and bearish technicals (price well below major moving averages with negative MACD). Corporate events add material downside risk via Nasdaq compliance uncertainty, while valuation provides only modest support given the negative P/E and no dividend yield data.
Positive Factors
FDA-approved commercial product
Having an FDA-approved, commercial-stage product (Mytesi) provides a durable revenue foundation and lowers clinical/regulatory risk versus pre-revenue peers. A marketed specialty GI therapy supports recurring prescription sales, established distribution channels, and optionality to leverage crofelemer into adjacent human and animal indications over time.
Negative Factors
Stressed balance sheet with negative equity
Negative stockholders' equity and rising leverage signal impaired capital structure and limit financial flexibility. This increases reliance on external funding, raises borrowing costs, can trigger covenants, and constrains the company’s ability to invest or absorb shocks without dilutive or restrictive financing solutions.
Read all positive and negative factors
Positive Factors
Negative Factors
FDA-approved commercial product
Having an FDA-approved, commercial-stage product (Mytesi) provides a durable revenue foundation and lowers clinical/regulatory risk versus pre-revenue peers. A marketed specialty GI therapy supports recurring prescription sales, established distribution channels, and optionality to leverage crofelemer into adjacent human and animal indications over time.
Read all positive factors
Jaguar Animal Health (JAGX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.47M
Dividend YieldN/A
Average Volume (3M)74.61K
Price to Earnings (P/E)―
Beta (1Y)2.58
Revenue Growth-1.52%
EPS Growth84.32%
CountryUS
Employees49
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-709.05
Shares Outstanding401,265
10 Day Avg. Volume94,254
30 Day Avg. Volume74,613
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.13
Price to Sales (P/S)0.19
P/FCF Ratio0.38
Enterprise Value/Market Cap18.52
Enterprise Value/Revenue2.60
Enterprise Value/Gross Profit4.48
Enterprise Value/Ebitda-0.83
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-4.2
Revenue Forecast (FY)$2.46M
Jaguar Animal Health Business Overview & Revenue Model
Company Description
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic, and debilitating diarrhea. The company operates through two ...
How the Company Makes Money
Jaguar Health primarily makes money through product revenue from sales of its FDA-approved prescription drug Mytesi (crofelemer). Revenue is generated by selling Mytesi into the U.S. market via commercial distribution channels (e.g., specialty/pha...
Jaguar Animal Health Earnings Call Summary
Earnings Call Date:Apr 07, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:Aug 19, 2026
Earnings Call Sentiment Neutral
The call presented meaningful strategic and clinical positives — a sizable non-dilutive upfront/licensing arrangement, manufacturing revenue upside, and compelling proof-of-concept data with 12%–37% reductions in parenteral support and a targeted NDA timeline (H1 2027) for MVID. However, these positives are balanced by near-term commercial and financial challenges: YoY revenue decline, sustained and growing operating losses (net loss to $53.6M; Non-GAAP recurring EBITDA loss $48.1M), declining Mytesi prescription volumes, and increased dependency on partner milestone payments and manufacturing revenue under the out-license. Overall, the call communicated promising development and BD catalysts that could be transformative long term but also highlighted significant short-term financial pressures and commercialization trade-offs.Positive Updates
Non-Dilutive Licensing Deal with Future Pak
Closed U.S. out-license for Mytesi and Canalevia-CA1 with $18M upfront (company reported $16M received at signing, $2M conditional), additional ~$20M in potential milestone and future payments, and roughly $3M–$4M of additional payments already received. Jaguar will continue to manufacture crofelemer and recognize manufacturing revenue; the deal provides immediate non-dilutive cash to fund rare-disease development.
Negative Updates
Declining Mytesi Prescription Volume
Mytesi prescription volume declined ~3.7% in 2025 vs 2024, declined ~5.8% in Q4 2025 vs Q3 2025, and declined ~12.2% in Q4 2025 vs Q4 2024. Company notes specialty pharmacy inventory dynamics contribute to variability between prescription and invoiced sales volume.
Read all updates
Q4-2025 Updates
Positive
Negative
Non-Dilutive Licensing Deal with Future Pak
Closed U.S. out-license for Mytesi and Canalevia-CA1 with $18M upfront (company reported $16M received at signing, $2M conditional), additional ~$20M in potential milestone and future payments, and roughly $3M–$4M of additional payments already received. Jaguar will continue to manufacture crofelemer and recognize manufacturing revenue; the deal provides immediate non-dilutive cash to fund rare-disease development.
Read all positive updates
Company Guidance
The company’s guidance centers on “continued business development” in 2026 with near-term clinical, regulatory and BD catalysts over the next 6–12 months and a clear goal to license its crofelemer rare-disease program: target filing of an NDA for MVID in first half of 2027 (MVID global prevalence ≈200 patients) following completion of a fully enrolled placebo‑controlled trial (with ongoing treatment‑only extension), pursuit of FDA Breakthrough designation and EMA PRIME, and parallel Phase II randomized double‑blind placebo‑controlled development in short bowel syndrome‑IF (SBS‑IF; U.S. patient estimate ≈12,000) where third‑party market estimates put opportunity at ~$8 billion; proof‑of‑concept investigator data in three pediatric IF patients showed parenteral‑support reductions of 12%–37% (12.5%–15.6% in two SBS patients, ~37% in one MVID), with even 5% reductions described as meaningful; financial guidance emphasizes non‑dilutive funding (Future Pak licensing: $18M upfront with $16M received to date, $2M conditional, ~$20M in potential milestones and >$3M additional payments reported, Future Pak also paid $3M tied to termination of a buy‑back provision), Jaguar to remain manufacturer and recognize manufacturing revenue, Q4 2025 net revenue ≈$3.2M (+5% vs Q3 2025 $3.1M; −8% vs Q4 2024 $3.5M), 2025 total net revenue ≈$11.5M (≈$11.2M from Mytesi and Canalevia‑CA1), Mytesi prescription volume down ~3.7% in 2025 vs 2024 (Q4 2025 vs Q3 2025 down ~5.8%; Q4 2025 vs Q4 2024 down ~12.2%), loss from operations increased $15.1M to $45.9M in 2025, Non‑GAAP Recurring EBITDA net loss $48.1M (2025) vs $35.9M (2024), net loss attributable to common shareholders $53.6M (2025) vs $38.5M (2024), and the company expects these clinical, regulatory and BD milestones to drive partnership discussions and additional non‑dilutive funding.Jaguar Animal Health Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
12
Very Negative
Cash Flow
20
Very Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 10.50M | 11.51M | 11.69M | 9.76M | 11.96M | 4.33M |
| Gross Profit | 6.08M | 7.74M | 9.73M | 7.72M | 9.94M | 2.00M |
| EBITDA | -32.67M | -45.91M | -36.66M | -32.76M | -33.38M | -42.37M |
| Net Income | -49.98M | -53.58M | -38.49M | -41.30M | -47.45M | -52.59M |
Balance Sheet | ||||||
| Total Assets | 37.43M | 38.32M | 53.42M | 50.76M | 47.45M | 53.27M |
| Cash, Cash Equivalents and Short-Term Investments | 7.28M | 968.00K | 8.00M | 6.47M | 5.47M | 17.05M |
| Total Debt | 34.31M | 43.61M | 36.53M | 37.09M | 34.84M | 29.36M |
| Total Liabilities | 53.19M | 57.01M | 46.93M | 45.87M | 48.81M | 41.41M |
| Stockholders Equity | -15.75M | -17.29M | 7.29M | 4.96M | -657.00K | 11.61M |
Cash Flow | ||||||
| Free Cash Flow | -7.62M | 5.77M | -29.61M | -33.24M | -34.78M | -34.98M |
| Operating Cash Flow | -7.59M | 5.80M | -29.38M | -33.24M | -33.10M | -34.97M |
| Investing Cash Flow | -41.00K | 149.00K | -231.00K | 0.00 | -1.68M | -6.00K |
| Financing Cash Flow | 12.09M | -44.33M | 31.20M | 34.23M | 23.18M | 43.94M |
Jaguar Animal Health Technical Analysis
Negative
1.28
Price Trends
11.01
Negative
18.96
Negative
40.75
Negative
Market Momentum
-2.54
Negative
27.11
Positive
61.42
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JAGX, the sentiment is Negative. The current price of 1.28 is below the 20-day moving average (MA) of 5.53, below the 50-day MA of 11.01, and below the 200-day MA of 40.75, indicating a bearish trend. The MACD of -2.54 indicates Negative momentum. The RSI at 27.11 is Positive, neither overbought nor oversold. The STOCH value of 61.42 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JAGX.
Jaguar Animal Health Risk Analysis
Jaguar Animal Health disclosed 65 risk factors in its most recent earnings report. Jaguar Animal Health reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 1 New Risks
1.
The growing use of AI systems to automate processes, analyze data, and support decision-making poses inherent risks. Q4, 2023
Jaguar Animal Health Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
43 Neutral | $1.47M | -0.04 | 1029.24% | ― | -1.52% | 84.32% | |
43 Neutral | $3.99M | -0.26 | -46.34% | ― | ― | 74.58% | |
42 Neutral | $5.03M | -0.63 | -203.36% | ― | ― | 93.30% | |
42 Neutral | $3.72M | -0.36 | -212.63% | ― | 66.12% | 91.75% | |
41 Neutral | $4.26M | -0.32 | -0.40% | ― | ― | 96.79% | |
40 Underperform | $5.75M | -1.06 | -246.04% | ― | ― | 54.48% |
* Healthcare Sector Average
JAGX
Jaguar Animal Health
3.67
-145.43
-97.54%
GLMD
Galmed Pharmaceuticals
0.60
-0.77
-55.91%
SNGX
Soligenix
0.39
-1.49
-79.41%
REVB
Revelation Biosciences
1.09
-29.69
-96.46%
DRMA
Dermata Therapeutics
1.25
-6.45
-83.77%
SXTP
60 Degrees Pharmaceuticals, Inc.
1.40
-7.98
-85.07%
Jaguar Animal Health Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Jaguar Animal Health Issues Series Q Preferred Stock
Neutral
May 19, 2026
On May 19, 2026, Jaguar Health entered into privately negotiated exchange agreements with Uptown Capital and Streeterville Capital, issuing a total of 908 shares of new Series Q Perpetual Preferred Stock in exchange for a combined $22.7 million re...
Delistings and Listing ChangesRegulatory Filings and Compliance
Jaguar Animal Health Granted Short Nasdaq Compliance Extension
Negative
May 7, 2026
On May 6, 2026, Jaguar Health received a decision from a Nasdaq Hearings Panel granting a short extension to regain compliance with Nasdaq’s listing rules, following a May 1, 2026 notice that it had fallen below the required 500,000 publicly...
Delistings and Listing ChangesRegulatory Filings and ComplianceStock Split
Jaguar Health Boosts Public Float to Regain Nasdaq Compliance
Positive
May 4, 2026
On May 1, 2026, Jaguar Health disclosed that a 1-for-35 reverse stock split, effective April 30, 2026, had reduced its publicly held common shares to about 401,226, putting the company below Nasdaq’s 500,000-share minimum and leaving it non-...
Delistings and Listing ChangesRegulatory Filings and ComplianceStock Split
Jaguar Animal Health Faces New Nasdaq Compliance Deficiency
Negative
May 4, 2026
On May 1, 2026, Jaguar Health reported that Nasdaq staff notified the company it was out of compliance with the exchange’s minimum 500,000 publicly held shares requirement following a 1-for-35 reverse stock split effected on April 30, 2026, ...
Delistings and Listing ChangesRegulatory Filings and ComplianceShareholder MeetingsStock Split
Jaguar Health Enacts Reverse Split to Maintain Nasdaq Listing
Negative
Apr 27, 2026
On April 24, 2026, Jaguar Health received a Nasdaq Hearings Panel decision allowing the company to maintain its Nasdaq Capital Market listing, provided it restores compliance with the $1.00 minimum bid price rule by May 15, 2026, by sustaining a c...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and ComplianceShareholder MeetingsStock Split
Jaguar Health Shareholders Approve Key Capital Structure Changes
Positive
Apr 21, 2026
Jaguar Health said stockholders approved all five proposals at a special meeting held on April 20, 2026, with 7.18 million of 12.42 million eligible common shares represented. Investors backed an amendment to boost authorized voting common stock f...
Delistings and Listing ChangesFinancial DisclosuresPrivate Placements and FinancingRegulatory Filings and Compliance
Jaguar Animal Health Regains Nasdaq Compliance Through Capital Infusions
Positive
Apr 9, 2026
Jaguar Health, Inc. reported that as of December 31, 2025, it had a stockholders’ deficit of approximately $18.7 million, which left the company out of compliance with Nasdaq Listing Rule 5550(b)(1) requiring at least $2.5 million in stockho...
Business Operations and StrategyPrivate Placements and Financing
Jaguar Animal Health Restructures Debt and Royalty Agreements
Positive
Mar 9, 2026
On March 6, 2026, Jaguar Health amended two $12 million royalty agreements with Uptown Capital and Streeterville Capital, delaying the start of monthly royalty payments from April 1, 2026 to July 1, 2026 and cutting each Royalty Repayment Amount b...
Delistings and Listing ChangesRegulatory Filings and Compliance
Jaguar Health Faces Nasdaq Delisting, Plans to Appeal
Negative
Mar 6, 2026
On March 5, 2026, Jaguar Health disclosed that it had received notice from Nasdaq that its common stock had closed below the $1.00 minimum bid price for 30 consecutive business days and that, due to its prior large reverse stock splits, it is not ...
DividendsRegulatory Filings and Compliance
Jaguar Animal Health Declares Special Series O Dividend
Neutral
Mar 3, 2026
On February 18, 2026, Jaguar Health’s board declared a special one-time dividend of one-tenth of a share of newly designated Series O Convertible Preferred Stock for each share of common stock outstanding, plus certain eligible warrants, wit...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.